Can nintedanib/Vigat cure pulmonary fibrosis and what is its clinical effect?

Nintedanib (Nintedanib) is a targeted therapeutic drug, mainly used to treat diseases related to pulmonary fibrosis, such as idiopathic pulmonary fibrosis (IPF), fibrosing interstitial lung disease (ILD), systemic sclerosis-related interstitial lung disease, etc. For patients with pulmonary fibrosis, nintedanib cannot cure the disease, but it plays an important role in slowing the progression of the disease and relieving symptoms.

Idiopathic pulmonary fibrosis is a chronic, progressive, and fatal lung disease in which the patient's lung tissue gradually hardens, leading to a gradual decline in lung function. Nintedanib can effectively slow down the progression of pulmonary fibrosis and delay the deterioration of patients' lung function by inhibiting a variety of fibrosis-related signaling pathways. This drug reduces fibrotic reactions and improves patients' quality of life by inhibiting the effects of fibrotic factors such as platelet-derived growth factor (PDGF), fibronectin (FGF) and transforming growth factor beta (TGF-β).

Although the use of nintedanib can slow the progression of pulmonary fibrosis, it does not completely cure the disease. During the course of treatment with nintedanib, the patient's condition may be controlled to a certain extent, but the symptoms of fibrosis in the lungs still exist, and the condition may continue to worsen after a period of treatment. Therefore, nintedanib is intended more as a disease management drug, designed to slow disease progression and reduce symptoms rather than cure the disease.

Clinical studies have shown that nintedanib has significant efficacy in the treatment of idiopathic pulmonary fibrosis and other types of fibrotic interstitial lung disease. Patients who used nintedanib had significantly slower decline in lung function and better maintenance of lung health. In addition, nintedanib can also improve patients' respiratory symptoms and reduce the number of hospitalizations and acute exacerbations caused by pulmonary fibrosis.

Keyword tags: nintedanib, Nintedanib, pulmonary fibrosis, therapeutic effect, idiopathic pulmonary fibrosis, clinical effect, disease course management, drug efficacy

Reference materials:https://www.nps.org.au/assets/medicines/193f52e8-0e32-45a1-8634-a5620080a313.pdf